drugset / Trial / NCT02171780

A Study to Assess Safety, Tolerability and Pharmacokinetics of Single Rising Inhaled Doses of BI 1744 CL in Healthy Male and Female Volunteers

NCT02171780

Phase 1 Completed 122 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

To investigate safety, tolerability, and pharmacokinetics of BI 1744 CL

Timeline

Start
2005-02
Primary completion
2005-07
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Olodaterol Small molecule 0.5 ug Inhaled
Subject Olodaterol Small molecule 70 ug Inhaled

Indications

No indication recorded.